cediranib + irinotecan + cetuximab

Cediranib + irinotecan + cetuximab is a three-drug combination therapy evaluated primarily in phase I trials for advanced solid tumors, including metastatic colorectal cancer. **Cediranib** is an oral, potent inhibitor of all three vascular endothelial growth factor receptors (VEGFR-1, -2, -3) and acts as an antiangiogenic agent, reducing tumor blood supply. **Irinotecan** is a topoisomerase I inhibitor (small molecule chemotherapy) that interferes with DNA replication and transcription, leading to cell death. **Cetuximab** is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking ligand-induced activation and downstream proliferative signaling. When used together, this combination aims to inhibit angiogenesis, disrupt tumor cell proliferation, and overcome resistance to standard chemotherapy, with investigational roles primarily in advanced solid tumors such as colorectal cancer[3].

Brand names

Campto

Other names

cediranib + irinotecan + cetuximab